{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:32:39Z","timestamp":1760549559420},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:00:00Z","timestamp":1404259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AILBologna","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Indolent non\u2010follicular lymphomas (inFLs) are generally regarded as incurable, apart from extranodal mucosa\u2010associated lymphatic tissue lymphomas, which can be partially cured by surgery, local radiotherapy, or antibiotic treatment. The aim of the present study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab (FMR) in inFL patients considering all the different entities belonging to this group. An observational retrospective study was conducted on 143 inFL patients providing that their first chemoimmunotherapy performed was FMR regimen and diagnosis from September 2000 to March 2011. There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas. At the end of treatment, overall response rate was 96.5% with 88% of complete responses (CR) and 8.5% of partial responses. With a median follow\u2010up of 48\u2009months, 10 out of 125 (8%) CR patients had disease relapse, yielding an estimated 9\u2010year disease\u2010free survival (DFS) of 74.9% and an estimated 10\u2010year overall survival of 92.8%. The estimated 9\u2010year progression free survival was 70.5%. The 10 relapsed patients showed lymphoma recurrence within 52\u2009months: after this time, the DFS curve presented a plateau configuration. Only two (1.4%) patients developed a secondary hematological neoplasia. This study showed promising findings for the use of a fludarabine\u2010based regimen in combination with rituximab in the front\u2010line treatment of symptomatic inFL with a noteworthy high percentage of CR associated to an interesting long\u2010term DFS and favorable acute and long\u2010term safety profile. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2151","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T10:15:04Z","timestamp":1404296104000},"page":"141-146","source":"Crossref","is-referenced-by-count":14,"title":["Fludarabine\u2013Mitoxantrone\u2013Rituximab regimen in untreated indolent non\u2010follicular non\u2010Hodgkin's lymphoma: experience on 143 patients"],"prefix":"10.1002","volume":"33","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u2018L. e A. Ser\u00e0gnoli\u2019 University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation.V2012.1.426.3798535","article-title":"The many faces of marginal zone lymphoma","volume":"2012","author":"Zinzani PL","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Progra"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91409-F"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1916"},{"key":"e_1_2_7_5_1","first-page":"830","article-title":"Utility of surgical resection with or without radiation therapy in patients with low\u2010grade gastric mucosa\u2010associated lymphoid tissue lymphoma","volume":"88","author":"Zinzani PL","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.V58.3.592.592","article-title":"The treatment of advanced stage favourable histology non\u2010Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation","volume":"58","author":"Hoppe RT","year":"1981","journal-title":"Blood"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low\u2010grade lymphoma","volume":"109","author":"Redmann JR","year":"1992","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058591"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008388824069"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.170"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07677.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12036"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq416"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072587"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065995"},{"key":"e_1_2_7_19_1","article-title":"Bendamustine and rituximab as first line treatment for patients with MALT lymphoma. An interim report of a phase 2 trial in Spain (GELTAMO MALT\u20102008\u201001)","volume":"22","author":"Salar A","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20234"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1226-z"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1337-6"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20237"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl126"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403440"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.02759.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31815203ad"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_34_1","first-page":"1236","article-title":"Management of nodal indolent (non marginal\u2010zone) non\u2010Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental hematology and Italian group for Bone Marrow Transplantation","volume":"90","author":"Barosi G","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02309.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20874"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2151","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T04:20:54Z","timestamp":1696479654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/hon.2151"],"URL":"https:\/\/doi.org\/10.1002\/hon.2151","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,2]]}}}